secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-11-22T23:59:59+00:00
Accession:  0001437749-24-035988
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations
---------------------------------------------------------------------

- MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.
- Early adoption exceeded expectations; launch within 8–12 weeks post-approval as previously guided.
- Indicated in combination with miglustat for neurological NPC in patients aged 2+.
- AmplifyAssist patient support program launched to address insurance and access barriers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924035988/0001437749-24-035988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924035988/zvra20241121_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer